HEALTH TECHNOLOGY

InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company

InfuSystem Holdings, Inc. | April 29, 2022

InfuSystem Announces

InfuSystem Holdings, Inc. a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it has entered into a three-year master service agreement with a leading global healthcare technology and diagnostic company, effective April 25, 2022.

As part of the master service agreement, InfuSystem will be providing its biomedical services, which include annual preventative maintenance and repair solutions, to a majority of the fleet of infusion pumps at hospitals and other medical facilities under contract with this tier one global healthcare company. Service will be conducted on-site at the acute care facility or off-site at one of InfuSystem’s seven service centers. This global healthcare technology and diagnostic company’s preferred customers’ infusion pump fleet consists of more than 300,000 pumps located in 1,200 medical facilities, including 800 hospital systems in the U.S. and Canada. This preferred national service agreement is estimated to generate approximately $10 to $12 million, after an initial ramp-up period, in annual revenue under InfuSystem’s DME service platform.

I am extremely pleased the tier one global healthcare company has entrusted InfuSystem to be their preferred national service provider. We will deliver our 'white glove' biomedical services for their infusion pump fleet throughout North America. This master service agreement could potentially lead to additional opportunities to serve this customer to provide other products and services we offer under our DME Services segment. The wide-ranging expertise and capabilities of our DME platform, along with our proven track record of industry-leading service, and our national network of service centers, were important factors in their decision to partner with InfuSystem.”

Richard DiIorio, Chief Executive Officer of InfuSystem

“This acute care service opportunity is the direct result of effectively integrating our biomedical services acquisitions and creating a highly effective operating unit to service tier one clients in order to drive growth and significantly expand market share. Our certified biomedical service teams will be deployed throughout North America to commence onboarding of the global healthcare company’s infusion fleet, and to conduct service and repairs on-site or at one of our national service centers. I believe this preferred national service agreement lays the foundation for long-term growth of our DME business and even greater expansion into the acute care space.”

“This master service agreement represents a significant milestone for the Company. It is a testament to our team’s hard work and dedication in providing industry-leading service and repair solutions. We look forward to a long and successful relationship for years to come,” concluded Mr. DiIorio.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.
 

Spotlight

Background Aims As numbers of maintenance hemodialysis patients are growing, debilitating conditions of muscle wasting and atrophy are becoming some of the greatest concerns in end-stage renal disease patients. Exercise training has various potential benefits in terms of prevention of a sustained decline in functional status.

Spotlight

Background Aims As numbers of maintenance hemodialysis patients are growing, debilitating conditions of muscle wasting and atrophy are becoming some of the greatest concerns in end-stage renal disease patients. Exercise training has various potential benefits in terms of prevention of a sustained decline in functional status.

Related News

HEALTH TECHNOLOGY

Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

Nanomix Corporation and BIOASIA PTE LTD. | August 24, 2022

Nanomix Corporation a leader in the development of mobile, affordable, point-of-care diagnostics, announced that it has entered into a distribution agreement with BIOASIA PTE LTD a medical diagnostics distributor located in Singapore. Bioasia will market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system. “We are pleased to introduce and give access to much needed, new diagnostics to our hospitals and customers. Sepsis and critical infections are a challenge in Singapore in the same way they are around the world. Our partnership with Nanomix will help us bring a unique option to our customers and the healthcare system in Singapore.” Henry Lim, Managing Director of Bioasia Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “Nanomix is at the cusp of commercialization and continues to show early successes in executing upon our commercialization strategy. We are excited to see increased interest in our products especially in Asia, beginning in Singapore, which represents a significant and untapped growth opportunity for Nanomix.” John Hardesky, Chief Commercial Officer of Nanomix, stated, “Singapore has been ranked as one of the most efficient healthcare systems in the world for many years. The Nanōmix eLab® analyzer runs the S1 Panel assay rapidly, diagnosing critical infections including sepsis in 12 minutes which will undoubtedly lead to breakthroughs in earlier sepsis patient diagnosis.” Sepsis is a recognized global health crisis. Early identification and treatment are a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually. The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration. About BIOASIA PTE LTD Bioasia was established in 2005 focusing on medical marketing and distribution of critical care products and monitoring equipment for patients requiring intensive care in intensive care settings. Our staff are professional biomedical engineers with knowledge of ISO13485. We work with medical professionals in hospital settings to ensure in-hospital equipment are at optimal working conditions for effective patient monitoring and results. Bioasia has represented various medical device companies in Singapore and Brunei markets since 2005. Bioasia is GDPMDS certified. About Nanomix Corporation Nanomix is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.

Read More

HEALTH TECHNOLOGY

McKesson Signs Agreement to Acquire Rx Savings Solutions

McKesson Corporation | September 20, 2022

McKesson Corporation announced that it has signed a definitive agreement to acquire Rx Savings Solutions a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients. The transaction is valued up to $875 million, which includes a $600 million upfront payment and a maximum of $275 million of consideration contingent upon RxSS’ financial performance through calendar year 2025. The transaction is subject to customary closing conditions, including regulatory review, and is expected to close in the second half of Fiscal 2023. “Rx Savings Solutions’ offerings for employers and patients will strengthen McKesson’s ability to help solve the most common medication challenges related to access, affordability and adherence. We expect the acquisition of Rx Savings Solutions to accelerate McKesson’s growth priority in biopharma services by extending our ecosystem of differentiated medication access solutions to patients. Together with Rx Savings Solutions, McKesson will amplify our efforts to advance health outcomes for all.” Brian Tyler, chief executive officer, McKesson “This combination brings together two highly complementary organizations with closely aligned goals and values. By joining McKesson, we will be able to offer an exceptionally broad set of services to our clients and strengthen our leadership in prescription price transparency,” said Michael Rea, a clinical pharmacist who founded and currently leads Rx Savings Solutions. “This is a critical part of our growth journey, and we are excited about what the future holds for Rx Savings Solutions as part of McKesson.” RxSS contracts directly with health plans and large self-funded employers to maximize the effectiveness of benefit design to drive prescription cost savings for members. The company uses an evidence-based, proprietary machine-learning algorithm to help members understand available options for therapy and identify cost-effective prescription alternatives under their insurance. If a prescription change would benefit the member, RxSS provides assistance to update the prescription. The company also provides ongoing medication reminders to help improve adherence. Following the closing of the transaction, RxSS will become part of the company’s Prescription Technology Solutions business, which works across the healthcare delivery system to offer next-generation patient access, affordability and adherence solutions. The combined organization will endeavor to bring new capabilities for employers and patients to McKesson’s broad portfolio of pharmacy, provider, payer, and biopharma services. After initial integration, McKesson expects to use the combined medication access, affordability, and adherence services as a foundation to build new outcomes management programs for biopharma and payers, differentiated by their reach and efficacy at three touchpoints: provider office, pharmacy counter, and direct patient tools. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories. About Rx Savings Solutions Founded by pharmacist Michael Rea, Rx Savings Solutions helps members and payers reduce prescription drug costs through a combination of clinical technology, transparency, member engagement and concierge support. Currently 17 million members have access to personalized recommendations for lowering prescription costs and dedicated pharmacy experts to help navigate benefits, providers and pharmacies.

Read More

HEALTH TECHNOLOGY

Eleos Health and The Echo Group Announce Strategic Partnership to Advance the use of Augmented Intelligence in Behavioral Health

Eleos Health and Echo Group | September 16, 2022

Eleos Health, the leader in CareOps Automation for behavioral health, and The Echo Group, the only provider of visual electronic health record technology, announced that Eleos Health's augmented intelligence will be directly embedded into the EchoVantage web-based clinical, billing, and administrative EHR application to serve the needs of behavioral healthcare clinicians. Eleos Health and EchoVantage will act in synergy to reduce administrative burdens on clinicians. Medical professionals face an increasing number of administrative tasks, spending an average of 20% of their total working hours on administration. In general, notes for each session take about 15 minutes to complete, with the average full-time clinician doing so for 40 sessions per week. Eleos will turn behavioral health conversations into documentation and session intelligence, plugging directly into EchoVantage's visual health record (VHR). The VHR provides clinicians with a client's case across a timeline, with visual indicators providing an understandable and actionable graphical format. Clinicians using Eleos reduce time spent on documentation by over 30%. This increase in efficient and accurate documentation also equips supervisors with unprecedented visibility into staff activity, caseloads and performance to make it easier for providers to meet organizational standards for documentation, while empowering providers to improve training with structured, objective feedback on their sessions. "Eleos Health is excited to add The Echo Group to our growing base of strategic partners who are dedicated to advancing the standard of care in behavioral health. By enhancing the EchoVantage EHR with our augmented intelligence capabilities, we will give clinicians the ability to spend less time on administrative tasks and more time impacting the lives of those managing behavioral health conditions," Alon Joffe, CEO and Co-Founder, Eleos Health EchoVantage ensures that all aspects of the clinical chart are fully integrated and organized, along with the timeline, in relation to each other. This lends true clinical understanding to precipitating events and treatment activities. "The expansion of our national offering to include Eleos Health as an embedded platform for all of our customers is a huge benefit for clinicians and their patients," said Allan Normandin, Chief Executive Officer, The Echo Group. "The Echo Group is focused on finding ways to empower our customers to be more clinically effective and financially strong. Working with Eleos Health is another step in achieving that goal by reducing the barrier of administrative tasks in the continuum of care." This partnership puts overburdened clinicians back into the office working with clients instead of spending their time typing notes into their EHR. Beyond simplifying documentation, , this partnership will enable clinicians to quickly understand the themes in their meetings, such as suicidal thoughts or cognitive-behavioral therapy techniques, and pursue the best evidence-based practices. Eleos Health's proprietary voice-based Natural Language Understanding (NLU) technology accurately identifies evidence-based techniques, as well as interprets the meaning of behavioral health conversations, giving clinicians objective feedback they can use with patients to identify recurring themes, issues and needs. Eleos Health will be available to all of The Echo Group's clients as an add-on, with GRAND Mental Health, in Northeastern and North Central Oklahoma, being the first center to leverage the power of both systems to help give its care providers more time for patients. The Echo Group's partners are located throughout the U.S. and range in size, from small community behavioral health agencies to comprehensive enterprise-wide organizations. "The ability to reduce administrative burdens for clinicians while also increasing visibility around the quality of care is invaluable in giving our staff the freedom and tools they need to focus on our mission of improving quality of life for consumers," said Josh Cantwell, COO, GRAND Mental Health. "The Eleos Health and Echo Group partnership will meaningfully ability to support clinicians and serve our communities." About Eleos Health Founded in 2020, Eleos Health turns behavioral health conversations into documentation and intelligence that drives better care. Using proprietary, voice-based Natural Language Understanding (NLU) technology built by clinical experts to accurately interpret, analyze and document behavioral health conversations, Eleos reduces the operational burden on providers while unlocking objective insights into evidence-based care and the therapeutic alliance. Leadership teams can scale supervision and training while gaining unprecedented visibility into staff activity, caseloads and performance as well as population health. Eleos is the only technology of its kind that embeds seamlessly into electronic health records (EHRs), telehealth tools and existing provider workflows. With Eleos CareOps Automation, behavioral health providers are setting a new standard for care. About The Echo Group The Echo Group, privately held since 1980, revolutionized electronic health records in the behavioral health industry with EchoVantage, the only EHR featuring a visual continuum of care timeline. EchoVantage is a core, integrated EHR platform with a complete suite of tools designed to conform to your workflow, meet compliance requirements, and increase productivity, enabling you to spend more time putting your clients. The Echo Group is located in Conway, New Hampshire, with an additional office in California. Echo has more than 80 employees dedicated to making the best behavioral health technology in the industry.

Read More